Document is current
Any future updates will be listed below
-
Authors
Khan, Sajid https://orcid.org/0000-0003-1331-8846
Kellish, Patrick
Connis, Nick https://orcid.org/0000-0001-5725-0674
Thummuri, Dinesh
Wiegand, Janet
Zhang, Peiyi
Zhang, Xuan
Budamagunta, Vivekananda
Hua, Nan
Yang, Yang
De, Umasankar
Jin, Lingtao
Zhang, Weizhou https://orcid.org/0000-0002-8236-0346
Zheng, Guangrong https://orcid.org/0000-0002-8106-6663
Hromas, Robert
Hann, Christine
Zajac-Kaye, Maria
Kaye, Frederic J. https://orcid.org/0000-0001-8565-1854
Zhou, Daohong
-
Funding
Funding for this research was provided by:
U.S. Department of Health & Human Services | National Institutes of Health (R01 CA241191, R01 CA219836, R01 CA260239, R01 CA260239, R01 CA242003, R01 CA241191, R01 CA242003, R01 CA241191, R01 CA219836, R01 CA260239)
U.S. Department of Health & Human Services | National Institutes of Health
U.S. Department of Health & Human Services | National Institutes of Health
U.S. Department of Health & Human Services | National Institutes of Health
U.S. Department of Health & Human Services | National Institutes of Health
U.S. Department of Health & Human Services | National Institutes of Health
Florida Department of Health (8JK04, 8JK04)
U.S. Department of Health & Human Services | National Institutes of Health
U.S. Department of Health & Human Services | National Institutes of Health
U.S. Department of Health & Human Services | National Institutes of Health
U.S. Department of Health & Human Services | National Institutes of Health
- License Information
-
More Information
Article History
Received: 30 September 2022
Revised: 20 December 2022
Accepted: 22 December 2022
First Online: 2 January 2023
Competing interests
: SK, DT, PZ, GZ, and DZ are inventors of two patent applications for use of BCL-X<sub>L</sub> PROTACs as senolytic and antitumor agents. RH, GZ, and DZ are co-founders of and have equity in Dialectic Therapeutics, which develops BCL-X<sub>L</sub>/2 PROTACs to treat cancer.
